Saturday, 31 October 2026European Markets

ATOS Stock Plummets Over 21% On Tuesday: What's The Reason?

Loading stream...

(vianews) - according to recent data, atos shares (cac 40: ato.pa) experienced an unprecedented 21.67% drop at 14:50 est on tuesday - this drop followed two consecutive sessions of losses and yet cac 40 index is showing an uptick of 0.27% at eur8,170.13, seemingly defying downward trends seen earlier. although recent volatility could still occur within this market environment, bullish trends seem more prevalent now.

about atos

atos se is a leading global provider of digital transformation solutions, providing services such as advanced computing, analytics, ai and automation; cloud solutions; customer journey analytics; digital consulting services; workplace solutions for modern applications and platforms; edge computing as well as cybersecurity and infrastructure services for industries including financial services, healthcare, manufacturing, public sector resources telecom media entertainment. established in 1982 and based out of bezons france.

technical analysis

volume atos recently experienced an extraordinary trading volume increase of 185.19% above its average volume of 2,492,940 - this represents significant interest among investors for this stock. atos has experienced various levels of volatility over the last week, month, and quarter. last week's intraday variation average was positive by 0.82% while in july it recorded negative variance by 0.19%; during q3, atos saw its intraday variation average turn positive with an impressive increase to 5.0% (+5% last month and 5.0%+1% last quarter). atos saw the highest amplitude average volatility at 4.99% per week (4.999% +4.54% last month +5.07% last quarter).

equity analysis

earnings per share (eps) is a financial metric used to measure how much of a company's profit is allocated per outstanding share of stock. according to this text, atos currently boasts a trailing 12-month eps of eur-10.01. atos' annual loss per share stands at eur10.01, suggesting it has experienced financial difficulties over the last 12 months and may no longer be profitable. such information can assist investors in assessing atos' financial performance as well as its future growth potential and profitability.

more news about atos (ato.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com